Algeria vs Panama: HIV/AIDS deaths averted by antiretroviral therapy
Algeria
1,007 deaths
in 2024
Panama
934.45 deaths
in 2024
Algeria rank
73rd
Panama rank
76th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Algeria
- Panama
How they compare
Algeria currently reports 1,007 deaths against 934.45 deaths in Panama, a difference of 72.55 deaths.
That makes Algeria's figure about 1.1 times Panama's.
The two have swapped places 3 times across 35 shared years of data; in 1990 it was Panama ahead.
Algeria ranks 73rd and Panama ranks 76th of 157 countries.
Across the 4 decades both report, Algeria averaged higher in 1 and Panama in 3.
Head to head by decade
| Decade | Algeria | Panama | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 4.15 deaths | 8.02 deaths | 3.87 deaths | Panama |
| 2000s | 78.66 deaths | 346.22 deaths | 267.56 deaths | Panama |
| 2010s | 458.68 deaths | 668.17 deaths | 209.49 deaths | Panama |
| 2020s | 900.71 deaths | 769.48 deaths | 131.23 deaths | Algeria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Algeria or Panama?
- Algeria, at 1,007 deaths against 934.45 deaths in Panama as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Algeria and Panama?
- 72.55 deaths, with Algeria ahead.
- How many years of comparable data are there for Algeria and Panama?
- 35 years are reported by both, from 1990 to 2024.
- How do Algeria and Panama rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Algeria ranks 73rd and Panama ranks 76th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.